US Equities Analysis

VRTX — Vertex Pharmaceuticals

VRTX Price Chart FCF Yield Dividend Yield Price / Earnings Price / Book EV / EBITDA EV / NOPAT Consensus EPS Broker Sentiment EBITDA Margin EBIT Margin ROIC & ROE Capital Turnover Capex & WC / Sales Net Debt / Equity Price and 100d MA Relative to Index Relative to MSCI


1. Industry Fundamentals

1.1 Cyclicality

The company operates in a cyclical industry sensitive to macroeconomic conditions. Revenue and earnings tend to correlate with broader economic cycles, with periods of expansion driving growth and contractions creating headwinds. Current market capitalisation: 110.59B.

1.2 Competition

The industry is moderately competitive with established players and meaningful barriers to entry. Beta of 0.31 suggests moderate market sensitivity. Competitive advantages stem from brand, scale, or regulatory moats.

1.3 Technology

Key technology drivers include digital transformation, operational efficiency, automation. Companies that invest in R&D and adopt new technologies tend to gain market share. The pace of technological change creates both opportunities for innovation and risks of disruption.


2. Company Fundamentals

2.1 Competitiveness

Metric Value
Operating Margins 38.13%
Profit Margins 35.51%
Return on Equity 24.2%
Return on Assets 12.14%
Free Float 0.25B
Short Int % Utilisation 2.0%

2.2 Growth

Metric Value
Revenue Growth 7.8%
Free Cash Flow 2.78B
EBITDA 21.14 (Ratio)
Enterprise Value 105.33B
EV/Revenue 8.62
EV/EBITDA 21.14

Revenue growth of 7.8% indicates steady, moderate expansion.

2.3 Management

Role Metric
Consensus Rating N/A

2.4 Return

Metric Value
Expected Return (Ann.) 20.50%
Risk / Std Dev (Ann.) 28.53%
Sharpe Ratio (rf=4.5%) 0.56
Beta 0.31

2.5 Valuation

Metric Value
P/E (Forward) 20.29
Price/Book 6.15
EV/Revenue 8.62
EV/EBITDA 21.14
Enterprise Value / NOPAT 28.87
FCF Yield (%) 2.34%
Price / Earnings 27.78
Price / Book 6.15
Enterprise Value / EBITDA 22.81

Forward P/E of 20x is at a moderate premium, reflecting growth expectations.

2.6 Return Outlook

The stock’s historical risk-return profile shows an annualised expected return of 20.5% with annualised volatility of 28.5%, yielding a Sharpe ratio of 0.56 (rf=4.5%). The risk-adjusted return is attractive relative to the risk-free rate. With a beta of 0.3, the stock is less volatile than the market, offering relative downside protection.


us-equitystockequityvrtxhealth-carebiotechnologynasdaq